Skip to main content
MedPathMedPath Home
Clinical Trials/2025-524328-24-00
2025-524328-24-00
Recruiting
Phase 1

GRT-1C102: A randomized, double-blind, placebo-controlled dose escalation study to evaluate the safety, tolerability, and pharmacokinetics/pharmacodynamics of GRT-001 after subcutaneous administrations to healthy subjects (MONOSqut trial).

Granite Bio AG1 site in 1 country40 target enrollmentStarted: April 1, 2026Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsUlcerative colitis

Overview

Phase
Phase 1
Status
Recruiting
Enrollment
40
Locations
1
OverviewEligibility CriteriaInvestigatorsSitesRecords & IdentifiersSimilar Trials

Overview

Brief Summary

No summary available.

Eligibility Criteria

Ages
18 years to 64 years (18-64 Years)
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Investigators

Sponsor Class
Pharmaceutical company
Responsible Party
Principal Investigator
Principal Investigator

CT information desk

Scientific

Granite Bio AG

Study Sites (1)

Loading locations...

Similar Trials

Withdrawn
Phase 1
A phase 1, randomized, double-blind, placebo-controlled study investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending doses of VNA-318 in healthy male subjects
2024-512106-26-00Vandria SA96
Not yet recruiting
Phase 1
A phase 1, double-blind, placebo-controlled, randomized, single ascending dose and multiple ascending dose study to assess the safety, tolerability, and pharmacokinetics of GHF-201 in healthy adult volunteers
2024-519813-74-00CCDRD Cooperative Clinical Drug Research and Development AG, GHF-Golden Heart Flower Ltd.32
Recruiting
Not Applicable
A Phase IIb Study of the Efficacy and Safety of AZD5148 to Prevent Recurrence of Clostridioides difficile InfectionClostridioides difficile infection
jRCT203125057910
Recruiting
Not Applicable
A study to evaluate the effectiveness and safety of setidegrasib, given with either mFOLFIRINOX or NALIRIFOX chemotherapies, in people with pancreatic cancerKRAS G12D-mutated Metastatic Pancreatic Adenocarcinoma
jRCT2031250772614
Recruiting
Not Applicable
A Phase 3 Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features,in Bipolar-I Disorder TakingLithium, Valproate, or Lamotrigine (CN0120046)Bipolar-I Disorder
jRCT204125017027